Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$13.42 - $23.38 $590 - $1,028
-44 Reduced 0.1%
45,557 $631,000
Q4 2021

Feb 14, 2022

SELL
$12.78 - $23.74 $7,808 - $14,505
-611 Reduced 1.32%
45,601 $1.08 Million
Q3 2021

Nov 15, 2021

SELL
$11.73 - $16.08 $23,108 - $31,677
-1,970 Reduced 4.09%
46,212 $609,000
Q2 2021

Aug 16, 2021

SELL
$12.85 - $16.2 $783 - $988
-61 Reduced 0.13%
48,182 $747,000
Q1 2021

May 13, 2021

BUY
$13.84 - $17.8 $667,683 - $858,725
48,243 New
48,243 $696,000
Q4 2019

Feb 14, 2020

SELL
$13.91 - $21.48 $997,249 - $1.54 Million
-71,693 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$15.84 - $30.01 $258,334 - $489,433
-16,309 Reduced 18.53%
71,693 $1.14 Million
Q2 2019

Aug 14, 2019

BUY
$17.38 - $26.88 $1.53 Million - $2.37 Million
88,002 New
88,002 $2.37 Million

Others Institutions Holding MGTX

About MeiraGTx Holdings plc


  • Ticker MGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,010,700
  • Market Cap $292M
  • Description
  • MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...
More about MGTX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.